PF-Atlas › Clinical Trials › NCT06265532
Collagen-targeted Positron Emission Tomography Imaging for Assessment of EGCG Effect
EGCG 300 mg · Phase 1
Registry ID
NCT06265532
Phase
Phase 1
Status
Completed
Drug / intervention
EGCG 300 mg
Sponsor
Hal Chapman
Start
2024-02-07
Enrollment
12
Locations
3
About this trial
The primary purpose of this substudy is to determine if collagen-targeted PET using the type 1 collagen-targeted PET probe, Gallium-68 (68Ga)-labeled collagen binding probe 8 (CBP8) can inform as to drug effect of EGCG and assist in dose selection.
Explore related
Medical disclaimer. This page summarizes public trial data for NCT06265532 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.